Hepatocyte CD36 plays a major role in driving de novo lipogenesis and in the development of MASLD (Koonen et al., 2007; Rada et al., 2020; Wilson et al., 2016). This evidence concerns the gene CD36 and metabolic dysfunction-associated steatotic liver disease.